Bioprocessing in Vaccine Development and Manufacturing

Solutions for vaccine process development through production

In these exceptional and unprecedented times, many companies and organizations are eagerly working to advance the development of a vaccine in the context of the current COVID-19 crisis.

New bioprocess technologies such as single-use equipment and process automation open up novel possibilities for quality control and validation. This is especially important in GMP regulated environments such as in the development and manufacturing of new influence vaccines. When facing a pandemic outbreak, the need to smoothly develop new processes and quickly scale-up to clinical production volumes is key to efficiently develop new vaccinations.

Eppendorf, your expert partner in bioprocessing, contributes with its bioprocess solutions and services.

Vaccine; vaccines; Vaccination development; vaccine bioprocessing; vaccine manufacturer; Eppendorf; Expert partner

Challenges in vaccine upstream bioprocessing

Vaccine manufacturers are facing the challenge of developing new products to serve so far unmet needs and fulfilling the demands on dose numbers in an economically viable way. Upstream bioprocessing is an important piece of the puzzle. Read expert views and case studies on some of the hot topics in vaccine bioprocess development.

Download eBook (PDF)

eBook about challenges and success factors in viral vector production, continuous bioprocessing, and process scale-up.

Article about Vaccine Reserach and process development

Process development is an important factor when creating a modified and lower-cost methods for production.

Vaccine research and process development

Modifying vaccines in response to changes by the respective virus or agent is a constant challenge for vaccine manufacturers. Hence, process development is a key element in the creation of improved, more rapid, and lower-cost methods for production.

Download publication (PDF)

Viral vector production

Viral vectors are used in molecular biology research, gene therapy applications, and in vaccine development. High yield, scalability, robustness and commercial viability are some of the demands bioprocess engineers impose on bioprocesses for viral vector production. Cell & Gene Therapy Insights has talked with our colleagues Ankita Desai and Dr. Philipp Nold, bioprocess field application specialists, about the challenges they see in upstream bioprocess development for viral vector production.

Download interview (PDF)

Interview with Philip Nold and Ankita Desai about viral vector production

Viral vectors are used in vaccine development.

Application Note on the development of a scale-down model for rAAV viral vector productions with Généthon

Eppendorf and Généthon used the DASbox Mini Bioreactor to develop a scale-down model for rAAV viral vector production.

Researchers at Généthon^® developed a scale-down model for rAAV viral vector production in a Sf9/BEV system using a DASbox Mini Bioreactor System. They reproduced cell growth and production performance. The DASbox system allowed the comparison of different experimental conditions in parallel runs, which accelerated scale-down model development.

Download application note (PDF)

Researchers at Cevec Pharmaceuticals adapted the small scale shake flasks rAAV production process to stirred-tank bioreactors and scaled it up from a working volume of 2 L to 10 L, using BioBLU Single-Use Vessels. It led to comparable cell growth and virus production at both scales and to the original shake flask process.

Download application note (PDF)

Application Note about rAAV production in suspension CAP GT cells with Cevec Pharmaceuticals

Cecev Pharmaceuticals; Eppendorf; rAAV production; vaccine process development; BioBLU; singe-use

Application Note on transient lentiviral vector production using a BioFlo 320 with a BioBLU 5p

Lentiviral vectors (LVs), which are especially applicable to gene therapy, are promising vector types for the clinical trials of such treatments. This application note describes the first successful experimental setup to cultivate LVs in HEK 293T cells adherently grown on Fibra-Cel^® disks in a BioBLU 5p Single-Use Vessel.

Download application note (PDF)

Perfusion culture systems

Continuous cultivation techniques and perfusion have the potential to increase the efficiency of biopharmaceutical manufacturing processes. They can help increasing product titers while decreasing production volumes needed.

> Download application: High-density Vero cell perfusion culture

> Download application: Small scale perfusion using an ATF cell retention device

eBook on the cultivation of vero cells in packed.bed bioreactors

Vero cells are anchorage-dependent cells that are widely used as a platform for viral vaccine production. In stirred-tank bioreactors, they are grown ordinarily on microcarriers. Fibra-Cel^® disks are an alternative attachment matrix because they provide a three-dimensional environment that protects cells from damaging shear forces. The cultivation of Vero cells in benchtop single-use and glass bioreactors with a packed bed made of Fibra-Cel disks has been tested.

Download eBook (PDF)

Kamal A. Rashid, PhD, Director of the Biomanufacturing Education and Research Center, and Research Professor, Worcester Polytechnic Institute, reports on the cultivation of CHO cells in the BioBLU^® 5p Single-Use Vessel in perfusion mode. The packed-bed basket technology, developed by Eppendorf, provides a shear-free environment for the production of animal cells.

Download application note (PDF)

Application Note on leachable studies on mammalian cell culture

Single-use technology

Single-use bioreactors are routinely used in biopharmaceutical R&D and biologics manufacturing. They have the potential to reduce turn-around times and the risk for contaminations and make validations easier. One potential problem of single-use systems, however, is the release of chemical compounds into the culture medium. Standardized tests help investigating the effects of leachables and extractables (L&Es) on cell growth.

Download application note (PDF)

Microbial vaccine development

Recent surveys see an increasing demand of microbial expression systems in the biopharmaceutical industry. Their advantages are obvious: Bacterial hosts are easy to cultivate, grow fast, and media are less expensive than complex cell culture media. A growing range of single-use fermentors has the potential to diminish labor costs, shorten turn-around times, and make validation easier.

Download application note (PDF)

Application Note on scalability of parallel e.coli fermentations in BioBLU f single-use bioreactors

Interview with Charlotte Mignon, Research Engineer from BIOASTER

BIOASTER^® Technology Research Institute (TRI) is working to develop a microbial technology platform to improve safety and efficacy of vaccines and to develop diagnostic tools. They use a DASbox^® Mini Bioreactor System equipped with BioBLU Single-Use Vessels in order to enhance their process development efforts.

Charlotte Mignon, Research Engineer at BIOASTER, discussed her motivation on the job, what her research is about and how she spends her free time in an interesting interview.

Download interview (PDF)